The mechanisms of immune evasion by cancer cells are the targets of immunotherapies, and immune checkpoint inhibitors, including antibodies that block the programmed cell death of protein-1 (PD-1)/PD-L1 and the cytotoxic T lymphocyte associated protein 4 (CTLA-4), are receptors that attenuate T cell response. This evidence concerns the gene CD274 and cancer.